Erlotinib OSI/Roche/Genentech.

摘要: Erlotinib (CP-358774, OSI-774, Tarceva), a quinazoline derivative, is an orally active epidermal growth factor receptor tyrosine kinase inhibitor under development jointly by Genentech, OSI (formerly Oncogene Science) and Roche, both as monotherapy combination therapy for the potential treatment of solid tumors, including non-small-cell lung cancer (NSCLC) pancreatic, breast, head neck cancers [203487]. Development compound most advanced NSCLC pancreatic cancer; in July 2001, phase III trials were initiated [416835]. In October also [426704]. Japan, was I studies January 2002 [439189].